SCHEMBL874048

SCHEMBL874048

Cn1cncc1CC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 3/20 0.41
CHRM4 P08173 2/20 0.39
CHRM1 P11229 2/20 0.39
CYP2C9 P11712 2/20 0.39
CHRM3 P20309 2/20 0.39
LMNA P02545 2/20 0.39
CYP3A4 P08684 2/20 0.39
NFKB1 P19838 2/20 0.39
CHRM2 P08172 1/20 0.39
CYP2A6 P11509 1/20 0.39
CNR1 P21554 1/20 0.39
HTR2A P28223 1/20 0.39
CYP2A13 Q16696 1/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
ALOX15 P16050 1/20 0.39
ALOX12 P18054 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6775586 0.98 KDM4E (0.40) CHRM5CHRM4CHRM1CYP2C9CHRM3
SCHEMBL9372232 0.86 CHRM5 (0.41) CHRM5CHRM4CHRM1CYP2C9CHRM3
SCHEMBL25630920 0.86 CHRM5 (0.41) CHRM5CHRM4CHRM1CYP2C9CHRM3
SCHEMBL2892358 0.82 CHRM5 (0.43) CHRM5CHRM4CHRM1CYP2C9CHRM3
SCHEMBL1768417 0.81 CYP11B1 (0.41) CHRM5CHRM4CHRM1CYP2C9CHRM3
SCHEMBL20362420 0.79 CHRM5 (0.38) CHRM5CHRM4CHRM1CYP2C9CHRM3
SCHEMBL31369367 0.77 AGTR1 (0.38) CHRM5CHRM4CHRM1CYP2C9CHRM3
SCHEMBL12256550 0.77 HPGDS (0.41) CHRM5CHRM4CHRM1CYP2C9CHRM3
SCHEMBL27984196 0.76 GABRA5 (0.37) CYP3A4NFKB1CYP1A2KDM4EMAPT
SCHEMBL25243731 0.76 CHRM5 (0.38) CHRM5CHRM4CHRM1CYP2C9CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017189528-A1 CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME Ecolab USA, Inc. (US) 2017-11-02 WO claimed
US-20170306504-A1 CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME CHAMPIONX LLC 2017-10-26 US claimed
US-20260076944-A1 COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH UNIV CALIFORNIA (US) 2026-03-19 US disclosed
US-20260063642-A1 Methods for Assaying a Bodily Sample of a Subject AGENT S A S (FR) 2026-03-05 US disclosed
US-20250375505-A1 COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM UNIV CALIFORNIA (US) 2025-12-11 US disclosed
US-20250368614-A1 COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR Opna Bio SA (CH) 2025-12-04 US disclosed
EP-4654969-A1 COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR Opna Bio SA (CH) 2025-12-03 EP disclosed
US-20250295713-A1 COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES DERMBIONT, INC. 2025-09-25 US disclosed
US-20250258146-A1 QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP HUMAN METABOLOMICS INSTITUTE INC. (CN) 2025-08-14 US disclosed
US-12064459-B2 Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes DERMBIONT, INC. (US) 2024-08-20 US disclosed
WO-2024159067-A1 COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR Opna Bio SA (CH) 2024-08-02 WO disclosed
US-20040254159-A1 Heterocyclic kinase inhibitors ABBOTT LABORATORIES 2004-12-16 US disclosed
WO-2004076424-A1 HETEROCYCLIC KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-09-10 WO disclosed
US-6693123-B2 (4-(3-PYRIDYLAMINOMETHYLENE)-2-PHENYLBENZOYL)-N -METHYLMETHIONINE, METHYL ESTER FOR EXAMPLE; RESTENOSIS, HYPERPLASIA UNIVERSITY OF PITTSBURGH 2004-02-17 US disclosed
EP-0873123-B1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIV PITTSBURGH (US) 2003-04-09 EP disclosed
US-20020193596-A1 Inhibitors of protein isoprenyl transferases UNIVERSITY OF PITTSBURGH (US) 2002-12-19 US disclosed
EP-0873123-A4 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIV PITTSBURGH (US) 1999-02-03 EP disclosed
EP-0873123-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1998-10-28 EP disclosed
WO-1997017070-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1997-05-15 WO disclosed
EP-0216424-A1 Imidazoles, their preparation and their use as fungicides SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1987-04-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250375505-A1 COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM CYP27A1, LIPC, CYP46A1 CHRM5 4243/4885CHRM4 4182/4885CHRM1 4678/4885
US-20020193596-A1 Inhibitors of protein isoprenyl transferases LANCL1, FNTB, DHCR7 CHRM5 2822/4885CHRM4 4306/4885CHRM1 3980/4885
US-20040254159-A1 Heterocyclic kinase inhibitors MAP3K20, MAP3K19, MAP3K1 CHRM5 4843/4885CHRM4 4769/4885CHRM1 4664/4885
US-20250368614-A1 COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR YAP1, YES1, TEAD2 CHRM5 2530/4885CHRM4 1791/4885CHRM1 1150/4885
US-20260063642-A1 Methods for Assaying a Bodily Sample of a Subject BACE1, BACE2, PSEN1 CHRM5 686/4885CHRM4 478/4885CHRM1 162/4885
US-20260076944-A1 COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH IDO1, INMT, IDO2 CHRM5 344/4885CHRM4 470/4885CHRM1 658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.